Nilotinib 300 mg BID as frontline treatment of CML: prospective analysis of the Xpert BCR-ABL monitor system and significance of 3-month molecular response.
暂无分享，去创建一个
A. Nagler | F. Giles | S. Langabeer | M. McMullin | A. Alvarez-Iglesias | H. Fan | M. O'Dwyer | R. Swords | E. Conneally | P. le Coutre | R. Woodman